Clinical Trial Update: Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection? [Phase 3]

View source ↗

Summary

Phase 3 clinical trial assessing whether losartan and other ARBs influence outcomes in coronavirus infection, terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sars-cov Infection

Drugs mentioned

• ARB
• Losartan (losartan)

Snippet

Sponsor: University of British Columbia | Conditions: Covid19, SARS-CoV Infection | Phase 3 | Status: TERMINATED